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Abstract: Complete cytoreductive surgery is the cornerstone of the treatment of epithelial
ovarian cancer (EOC). The application of fluorescence image-guided surgery (FIGS) allows
for the increased intraoperative visualization and delineation of malignant lesions by using
fluorescently labeled targeting biomarkers, thereby improving intraoperative guidance. CD24, a small
glycophosphatidylinositol-anchored cell surface receptor, is overexpressed in approximately 70% of
solid cancers, and has been proposed as a prognostic and therapeutic tumor-specific biomarker for
EOC. Recently, preclinical studies have demonstrated the benefit of CD24-targeted contrast agents for
non-invasive fluorescence imaging, as well as improved tumor resection by employing CD24-targeted
FIGS in orthotopic patient-derived xenograft models of EOC. The successful detection of miniscule
metastases denotes CD24 as a promising biomarker for the application of fluorescence-guided surgery
in EOC patients. The aim of this review is to present the clinical and preclinically evaluated biomarkers
for ovarian cancer FIGS, highlight the strengths of CD24, and propose a future bimodal approach
combining CD24-targeted fluorescence imaging with radionuclide detection and targeted therapy.
Keywords: biomarker; intraoperative imaging; debulking surgery; complete resection; epithelial
ovarian cancer; optical imaging; CD24
1. Introduction
The aggressive surgical approach used to treat metastatic ovarian cancer is unique and remains
one of the therapeutic keystones, with the aim of achieving curative treatment. The overall survival
rate for epithelial ovarian cancer (EOC) is below 50%, mainly because the lack of early symptoms leads
to a late diagnosis in almost 75% of patients, followed by limited treatment options and emerging drug
resistance [1]. In 1975, Thomas Griffith was the first to show that besides the histological subtype,
the extent of residual disease after surgery impacts patient outcome [2]. The extent of residual disease
is classified into complete cytoreduction (0 cm) and macroscopic residual disease, which is further
subclassified into optimal (<1 cm) and suboptimal (>1 cm) cytoreduction [3]. The impact of complete
debulking has been confirmed in many trials as the most important prognostic factor for the survival
of EOC patients, and it has been suggested to increase the efficacy of subsequent drug therapies [3–5].
Clinical trials have also indicated that if macroscopic residual disease remains after surgery, the patient
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has no significant benefit compared to those who received suboptimal debulking, highlighting the
need for better tools to help surgeons achieve complete resection.
In clinical reality, complete debulking is not always feasible and can be challenging because of
aggressive tumor biology, histological subtype, advanced disease stage, and unresectable tumors
near vital structures [6–8]. To detect submillimeter and residual tumor lesions, the surgeon relies on
tactile and visual inspection, training, and experience. New technologies for preoperative planning are
warranted to help identify patients who will benefit from surgery, and for these patients, intraoperative
guidance methods to help achieve complete debulking are crucial for their survival.
One surgical technology that was developed to meet these criteria is fluorescence image-guided
surgery (FIGS). FIGS employs fluorescent molecules (fluorophores) as contrast agents, and together
with specialized imaging systems, the surgeon is provided with a screen image highlighting fluorescent
tumor tissue in the operating field. This technology has the capability to provide the surgeon with
real-time feedback and optimize the precision of resection, thus improving clinical outcomes. FIGS is
currently being assessed in ovarian cancer clinical trials, as well as for many other solid malignancies.
Ovarian cancer Phase I–III FIGS trials are being performed with untargeted dyes, such as indocyanine
green (ICG) [9] and contrast agents that target the folate receptor alpha (FRα). The first in-human FIGS
study was performed by Go van Dam et al. in 2011, in which they demonstrated the feasibility of FIGS
to improve the visualization of malignant lesions with a tumor-specific FRα-targeting probe, which had
high specificity for peritoneal metastases and left cancer-free tissue fluorescence negative [10]. In fact,
this tumor-specific fluorescence approach resulted in an increased resection rate for malignant tissue.
Since this first pilot study, FRα-targeting FIGS contrast agents have been improved, and there are
promising results from Phase II [11,12] and ongoing Phase III (NCT03180307) clinical trials. To expand
beyond folate and other clinically approved monoclonal antibodies (mAbs), much effort is being
dedicated to identifying new biomarkers for FIGS. Notably, the challenge faced when developing a
good imaging contrast agent for FIGS is the identification of both a biomarker that can discriminate
between malignant and healthy tissues and a dye capable of maximal tissue penetration which can be
detected with a dedicated and sensitive fluorescence imaging system. The biomarker-dye conjugate
also needs to exhibit low toxicity, high stability, and fast clearance to reduce unspecific signals [13].
Cluster of differentiation 24 (CD24) is a novel molecular target used for imaging, molecular-targeted
drug therapy, and immunotherapy [14–16]. Its high expression on tumor cells and rare expression
on healthy human tissue, where it is primarily found on hematologic cells, indicate its potential as a
tumor-specific biomarker [14–16]. A meta-analysis of 28 studies revealed that CD24 is overexpressed in
68% of human cancers, and CD24 expression was correlated with a higher self-renewal ability,
more metastases, and a poor prognosis [17]. In EOC, CD24 is almost uniformly (70.1–100%)
expressed [18,19]. We have demonstrated the ability of a CD24-targeting mAb conjugated with
near-infrared (NIR) fluorophores to identify tumor lesions in metastatic EOC patient-derived xenograft
(PDX) models with heterogeneous CD24 expression, supporting its potential to translate CD24-guidance
to the intraoperative setting for EOC patients [14,19]. Here, we review the emerging tumor-specific
biomarker CD24 as a target for FIGS, and focus specifically on EOC and the use of CD24 as a bimodal
biomarker for both imaging and theranostics.
2. Fluorescence Image-Guided Surgery
FIGS is a new strategy with the potential to (1) enhance the visualization of submillimeter
metastases, (2) improve tumor staging and risk stratification, (3) increase contrast between malignant
and healthy tissues, (4) optimize negative resection margins, (5) minimize damage to healthy structures,
and (6) confirm tumor cell-free resection beds intraoperatively in (7) real-time [20]. In a successful
debulking surgery with complete removal, all malignant lesions are resected, tumor cell-infiltrated
lymph nodes are removed, and negative tumor margins are achieved without damaging vital and
healthy structures [20]. In EOC clinical trials focused on the impact of residual disease, complete
debulking surgery (0 mm residual disease) was achieved in 33.5–37% of cases, while optimal debulking
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surgery was achieved in 64.7–74% of cases [3–5]. In addition, among several different solid cancers,
positive tumor margins occur in 8–70% of tumor resections, which correlates with local recurrence and
a poor prognosis [13,21,22]. Although FIGS appears to be an ideal emerging technology to help prevent
incomplete tumor surgeries, and several imaging probes have been shown to allow differentiation
between malignant and healthy tissues, the probes often fail to achieve sufficient contrast to clearly
delineate the tumor margins. This highlights the challenges facing the development of sensitive and
specific FIGS probes—the identification of compatible and suitable dyes, biomarkers, and imaging
technologies that together allow the specific targeting and intraoperative identification of malignant
lesions [23].
Dyes currently being investigated in fluorescence optical imaging technologies for clinical use
have shifted from those that emit in the visible light spectrum to dyes that emit in the NIR spectrum
(700–900 nm) [13,20]. The NIR spectrum offers reduced tissue autofluorescence, scattering, and tissue
absorption characteristics, therefore allowing deeper tissue penetration with better contrast compared
to the visible light spectrum (400–700 nm). Recent advances in NIR-II (900–1700 nm) fluorescence probes
(e.g., nanotubes) permit even deeper tissue penetration, a larger Stokes shift, and less photobleaching
than with organic dyes, achieving a superior resolution in the micrometer range [24]. Fluorescent
contrast agents offer the advantages of nonionizing properties and high temporal resolution. To date,
the only FDA- and EMA-approved NIR fluorescent contrast agents for FIGS are ICG (λex 783, λem 813)
and methylene blue (MB, λex 670, λem 690). These contrast agents can accumulate passively in tumors
because of the enhanced permeability and retention (EPR) effect caused by leaky blood vessels and
high interstitial pressure, but they are not targeted; therefore, they are not specific enough to reliably
guide tumor resection in most cancers [25].
Coupling NIR fluorophores to targeting molecules increases tumor specificity and decreases
false-positive signals. The targeting moiety can be an antibody, antibody fragment, peptide, or small
molecule; they vary in size from large macromolecules to small nanoparticles and accumulate in
tumor tissue through specific binding to antigens present on tumor cells or cells in the tumor
microenvironment [26]. The molecular size of the binding moiety influences the half-life circulation of
the targeting molecule and therefore determines the time point of surgery, with optimal fluorescence
signal intensity obtained from between 2 and 8 hours for small molecules and peptides, to 48–72 h for
antibodies [26]. To achieve this accumulation, the targeting molecule must first pass certain barriers
in the body to penetrate the tumor and reach its specific biomarker. The pharmacokinetic properties
of the probe are strongly influenced by the fluorophore, charge, labeling method, and solubility [27].
Next, to release a specific signal at the tumor, the fluorescent contrast agent has to bind the abundantly
expressed receptor with high affinity and not undergo unspecific accumulation elsewhere in the
body. Third, unbound molecules have to be rapidly cleared from the circulation through the liver and
kidneys to enhance contrast. Therefore, tumor biomarkers eligible for FIGS must meet the criteria
of highly specific tumor uptake, low unspecific binding, and rapid clearance. Together with the
dye, the conjugate has to exhibit minimal toxicity and high plasma stability. Notably, tumor lesion
sensitivity, which is necessary to produce the optimal signal-to-background ratio with the highest
contrast, is dependent on both the fluorescent and binding moieties [20].
Ultimately, emitted fluorophores have to be detected by fluorescence-guided surgery systems
with nanomolar-level sensitivity [28]. In open surgery systems, the detected fluorescent signal is
displayed on a screen, which means that FIGS does not interfere with the standard surgical field
or operative procedures. Other types of imaging systems also exist, such as fluorescence detection
integrated into endoscopic devices and robotic surgery systems [20]. To preserve the photostability of
the fluorophores, these camera systems are designed to keep the fluorescence excitation rate below
the photobleaching threshold of NIR dyes, avoiding irreversible photobleaching and allowing a
long-lasting intraoperative fluorescence signal [29]. In addition, to facilitate the translation of the
fluorescence signal displayed on a screen to the operation field, wide-field-of-view imaging goggles
(goggle navigation system) with an integrated overlay function represent a possible future solution [30].
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Multiple factors, such as tissue optical properties, depth, diffused fluorescence resolution, illumination
uniformity, and quantification of the fluorescence signal, influence imaging system performance and
acquired fluorescence intensities, making it difficult to standardize imaging systems [31]. Therefore,
quality control procedures for imaging performance and the quantification of fluorescence data are
necessary [32]. Emerging computational calculation methods can be exploited to process the large
amount of data and correct for autofluorescence and scattering. A technology based on fluorescence
lifetime analysis is capable of differentiating between true-positive and false-positive signals on the
basis of distinct fluorescent decay after excitation of the fluorophores [33]. This decay is independent
of fluorophore concentration, tissue scattering, and tissue depth.
In recent years, the number of early phase trials using FIGS has markedly increased. Because
of advances in (1) fluorescence imaging systems that detect, process, and quantify fluorescence,
(2) fluorescent contrast agent design (e.g., activatable probes, nanomolecular probes), and (3) the use
of fluorescent imaging beyond real-time guidance in combination with photothermal therapies,
immunotherapy, and antibody–drug conjugates, FIGS has the potential to revolutionize the treatment
and improve the outcomes of cancer patients.
3. Biomarkers Employed in EOC
To date, most biomarkers tested in clinical trials of FIGS are clinically approved mAbs evaluated
for molecular targeted therapy [13]. These GMP-manufactured antibodies have been found to be
safe, are readily available, and are more likely to become approved for clinical use. A biomarker
(biological marker) is “a characteristic that is objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic
intervention” [34]. Clinical biomarkers can be categorized as diagnostic, prognostic, or predictive.
Biomarkers that are tumor-specific and sensitive are needed to design targeted therapies; of particular
value are monoclonal antibodies because they selectively target tumor cells with high affinity and are
thus less cytotoxic to healthy tissue, unlike traditional chemotherapy in most cases. MAbs that target
biomarkers of EOC, such as cancer antigen 125 (CA125), epithelial cell adhesion protein (EpCAM),
vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and folate
receptor alpha (FRα), have been investigated in clinical trials of a molecular targeted therapy alone or
in combination with standard of care and have been extended following fluorophore conjugation to
FIGS (Table 1).
Table 1. Molecular biomarkers of ovarian cancer. The present and future.
Biomarker Preclinical/Clinical Purpose Ref.
CA125
Serum CA125 Clinically approved Screening
Oregovomab Phase I–III Immunotherapy [35]
B43.13-IRDye800CW Preclinical FIGS [36]
VEGF
Bevacizumab Clinically approved MTT *
Bevacizumab-IRDye800CW Preclinical FIGS [37]
EGFR
Trastuzumab (Her2) Phase II MTT [38]
Trastuzumab-IRDye800CW Preclinical FIGS [37]
Pertuzumab (Her2) Phase II MTT [39,40]
Pertuzumab-IRDye800CW Preclinical FIGS [41]
Her2 nanobody-IRDye800CW Preclinical FIGS [42]
Cetuximab (Her1) Phase II MTT [43]
EPCAM
Catumaxomab Phase II/III Immunotherapy [44,45]
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Table 1. Cont.
Biomarker Preclinical/Clinical Purpose Ref.
FRα
Farletuzumab Phase III MTT [46]
111In-farletuzumab-IRDye800CW Preclinical FIGS [47]
Folate-FITC Phase Ia FIGS [10]
EC17 Phase I FIGS [11]
OTL38 Phase I–III FIGS [12,48]
IR780-loaded folate-targeted
nanoparticles Preclinical FIGS [49]
MTT: molecular targeted therapy, FIGS: fluorescence image-guided surgery, CA125: cancer antigen 125, HE4: human
epididymis protein 4, FRα: folate receptor alpha, VEGF: vascular endothelial growth factor, EGFR: epidermal
growth factor receptor tyrosine kinase family. (* Bevacizumab was approved in 2011 based on the finding of two
clinical trials on front-line treatment for high-risk EOC patients (GOG218, ICON7) and in 2012 for recurrent EOC
patients based on the results of the GOG213 and OCEANS trials.).
In EOC, an increase in the serum level of CA125 is often observed before clinical symptoms occur,
representing the current gold standard for diagnosing and monitoring the treatment response and
disease progression. However, serum CA125 is not tumor-specific, varies between patients, and can
increase in response to various physiological conditions without neoplastic involvement, such as
endometriosis [50]. Targeting the CA125 surface antigen, which is expressed in more than 95% of all
non-mucinous EOC, has been suggested as a target for immunotherapy [35]. Despite CA125 being
almost ubiquitously expressed in epithelial ovarian tumors, and the most frequently used diagnostic
biomarker of EOC, this approach for immunotherapy has not shown a clinical benefit [35]. For FIGS,
however, CA125 is a potential tumor-specific biomarker [36]. The preclinical study by Fung et al.
explored the CA125-targeting antibody B43.13 conjugated to IR800 in orthotopic OVCAR3 and PDX
models, and found low background signals in healthy organs and specific uptake in CA-125-positive
PDX and primary tumors [36].
The accumulation of ascites due to increased vascular permeability and the early onset of
tumor angiogenesis is mediated by vascular endothelial growth factor (VEGF) overexpression [51].
The clinically approved (in 2011) mAb bevacizumab targets the tumor-promoting and
immunosuppressive molecule VEGF-A. Inhibition of the VEGF receptor results in decreased
accumulation of ascites, and increased progression-free survival and patient quality of life [51].
The family of epidermal growth factor receptor (EGFR)-targeted therapies, including trastuzumab,
pertuzumab and cetuximab, has been investigated in EOC patients, finding only moderate effects.
Trastuzumab targets the extracellular domain of HER2, which blocks tumor-associated signaling
pathways believed to reduce tumorigenicity and invasiveness and activates antibody-dependent
cellular cytotoxicity (ADCC). The low rate of HER2 overexpression, in only 11.4% of cases, together
with the low response rate reported in the first Phase II led to the conclusion that HER2 is not a suitable
target for EOC [38]. A preclinical evaluation of the targeting of VEGF and HER2 in intraperitoneal
ovarian cancer cell line models with IRDye800CW-labeled bevacizumab and trastuzumab reported
specific tumor detection in vivo, suggesting its potential as a targeting moiety for image-guided
surgery [37]. Of note, the dose-dependent tumor-to-background ratios were 1.93 (bevacizumab)
and 2.92 (trastuzumab), and it was possible to detect submillimeter metastases, although there were
high levels of unspecific signaling [41]. Nanobodies offer improved tissue penetration and rapid
blood clearance, and are therefore an attractive technology for the development of targeted imaging
probes. A HER2-targeting NIR-labeled nanobody has been developed, and preclinically, it was
demonstrated to enable the fast and highly sensitive detection of submillimeter-sized lesions with
decreased false-positive detection [42]. However, these experiments were performed on HER2+ Skov-3
intraperitoneally injected cell line models, and given the wide variation in HER2 expression in ovarian
cancer, more homogenously expressed biomarkers are required to further develop this approach.
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The trifunctional mAb catumaxomab targets CD3 on T-cells, Fc-receptors on innate immune cells,
and EpCAM on tumor cells, and it is heterogeneously overexpressed in epithelial cancers, including
EOC. It has been tested for molecular target therapy in Phase I–III EOC clinical trials. The results of
these studies indicate its efficacy in the management of ascites, but with only partial tumor response
in 5% of patients [44,45]. Disregarding its high abundance on epithelial tumor cells, EpCAM is also
expressed on healthy human epithelia, which is a suboptimal characteristic for an imaging biomarker.
Yet, EpCAM-IRDye800CW has been investigated in preclinical models of colon, breast, and head and
neck cancers, and it was found to aid in the identification of millimeter-sized metastases that were
missed by the naked eye [52].
The most thoroughly investigated biomarker for use in FIGS with EOC is FRα. FRα, also known as
FOLR1, has been reported to be expressed on 76% of histological EOC samples. The expression level is
dependent on the histologic subtype (highest in high-grade serous ovarian cancer (HGSOC)), FIGO stage
(increases with stage), and recurrence status (lower in primary EOC) [53,54]. Its low abundance in
nonmalignant tissues makes FRα an attractive target for several applications in EOC—molecular
targeted therapy with the mAb farletuzumab and the drug-conjugate vintafolide [54], targeted
photothermal therapy with IR780 NIR light irradiation [49], and FRα-targeted real-time fluorescence
imaging in debulking surgeries [10]. Molecular targeted therapy with farletuzumab was shown to
have a promising objective response rate of over 70% in a Phase II trial, but a randomized Phase III trial
with 1100 participants failed to show a benefit on median progression-free survival [46,55]. In contrast,
after the introduction of the first FRα-targeted fluorescence imaging probe to the intraoperative
setting, which enabled the tumor-specific visualization of ovarian cancer metastases during surgery,
folate-FITC (EC17) was evaluated in a larger EOC patient cohort [10,11]. Intraoperative guidance with
EC17 allowed the additional detection of 16% more metastases not identified by visual inspection
and palpation alone [11]. The fluorescence signal was specific in FRα-positive lesions, but high
false-positive detection rates occurred due to tissue autofluorescence, as the fluorophore is in the
visible fluorescence spectrum. To overcome this problem, folate was conjugated to a NIR fluorophore
(OTL38), and in Phase II EOC clinical trials, resection rates improved by 29% additionally detected
fluorescent lesions [48], with 48.3% of patients deriving a benefit from the superior detection of at least
one extra metastasis [12]. In both studies, false-positive signals (23% [32] and 10% [12]) were attributed
to specific binding to folate receptor β, which is expressed, for instance, on activated macrophages
in lymph nodes, and demonstrates that there is still a need for a more specific imaging probe for
EOC patients.
The implementation of clinically approved biomarkers in ovarian cancer as a target for FIGS has
demonstrated the feasibility and benefit of intraoperative fluorescence guidance for cytoreductive
surgeries. Apart from clinically evaluated ovarian cancer biomarkers, promising preclinical studies
are examining new biomarkers, such as integrins [56] and the gonadotropin-releasing hormone
(GnRH) receptor [57], which are not only able to detect minuscule tumor deposits but are also
uniformly expressed in many cancers, and thus widen the applicability of these imaging contrast
agents. The overexpression of the (αvβ3) integrin in many cancers, its low expression in normal tissues
(except kidney), and its internalization after binding the FIGS contrast agent were shown to result in
slower clearance and specific tumor uptake in subcutaneous ovarian A2780 and OVCAR-4 cell line
models [56,58]. These studies suggest that integrins, targeted by IntegriSense 680 and cRGD-deep-red
squaraine fluorophore, are promising targets for FIGS in EOC and other cancers, and breast cancer
integrin-targeted FIGS has already been used in clinical trials [13]. The GnRH antagonist peptide
conjugated to ICG has also been evaluated for preclinical FIGS [57]. The GnRH receptor is expressed
on 78% of EOC and on other hormone-related cancers, such as endometrial, breast and prostate cancers.
A study by Liu et al. reported high-affinity binding to GnRH receptor-expressing EOC cells and a
high tumor-to-background ratio, but also an increased fluorescence signal intensity in healthy organs
compared to ICG alone in metastatic xenograft models [57].
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4. CD24 Is Classified as a Cancer-Specific and Sensitive Biomarker for Fluorescence
Image-Guided Surgery
One of the preclinically evaluated and promising biomarker candidates is CD24. CD24 is a small,
heavily glycosylated mucin-like glycosylphosphatidylinositol (GPI)-linked cell surface protein that is
expressed on developing and regenerating tissues. CD24 plays a crucial role in the early maturation
during hematopoiesis and is physiologically expressed on premature lymphocytes (pre-B-cells),
granulocytes (neutrophils), some epithelial (e.g., keratinocytes, renal tubular epithelial cells), neural,
and pancreatic cells [59]. In contrast to its low expression in healthy tissues, the adhesion molecule
CD24 is almost ubiquitously expressed in EOC (70.1–100%) and in 68% of solid tumors, for many of
which surgical resection is a main therapeutic strategy, such as colorectal cancer, advanced pancreatic
cancer and gliomas [17] (Table 2). Its primarily membranous expression is advantageous, as it permits
superior antigen targeting without the need to be internalized into the cells. CD24 was found to be
membranously expressed in approximately 90% of EOC patients and in 100% of established orthotopic
EOC PDX models [19]. The low expression in healthy tissues together with its overexpression in
various malignant tumors (Table 2), suggest its tumor specificity and broad clinical applicability. As a
result, CD24 overexpression has been exploited as a diagnostic marker and as a marker for treatment
resistance and prognosis, and evaluated for targeted therapy [17,60,61].
Table 2. Expression of CD24 among malignancies.
Malignancy CD24 Positive Detection Method CohortSize (n) Biomarker Ref.
Bladder carcinoma
75% primary IHC 60 Therapeutic target [62]
(93.3% metastases)
63.2% IHC 125 Predictive [61]
Breast cancer
84.6% IHC 201 Prognostic [63]
Colorectal cancer
68.7% IHC 147 Prognostic [64]
(84.4%
cytoplasmatic)
90% IHC 398 Therapeutic target [65]
Epithelial ovarian cancer
70.1% IHC 174 Prognostic [66]
100% (cytoplasmatic) IHC 71 Prognostic [67]
84% IHC 56 Prognostic [68]
91% IHC 116 Diagnostic [18]
89.7% IHC 29 Imaging [19]
Esophageal squamous cell carcinoma
40.4% IHC 151 Prognostic [69]
Glioma
72.8% IHC(WB, RT-PCR) 151 Prognostic [70]
Hepatocellular carcinoma
66/68% mRNA 79/31 Diagnostic [71]
(91% p53mut HCC) (Northern Blot, PCR)
Non-small cell lung carcinoma
45% IHC 89 Prognostic [72]
Lymphoma
91% TMA 522 / [73]
Pancreatic cancer
26.9% IHC 67 Prognostic [74]
71.6% IHC 95 Predictive [75]
Prostate
48% primary IHC 102 Prognostic [76]
68% LN metastases 31
(Clear cell) Renal cell carcinoma
41.7% IHC 108 Prognostic [77]
IHC: Immunohistochemistry, TMA: tissue microarrays, LN: lymph node, HCC: Hepatocellular carcinoma.
Note: IHC staining intensities and the cut-off between positive (medium and high) and negative (weak and
absent) are not standardized among the cited studies.
In recent years, CD24 has evolved as an encouraging molecular biomarker for EOC [78] in the field
of immunotherapy, and as a tumor-specific biomarker for targeted drug delivery and imaging [14,16,19].
CD24 expression in ovarian cancer has been found to correlate with clinicopathological parameters,
such as higher tumor grade, higher tumor stage, omental metastasis, relapse, and a more aggressive
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course of the disease [17,66,79]. As already mentioned, complete debulking surgery is one of the
most important prognostic factors in EOC, with emerging evidence that patients with no macroscopic
residual tumor deposits have an increased survival benefit [2–5]. Based on available data bases,
complete debulking has a similar survival benefit in early-stage and advanced-stage disease [3].
The detection of metastases is additionally important during cytoreductive surgery to improve the
staging of the patient for adequate postsurgical treatment and to avoid radical surgery that may lead
to complications. In addition, a significant survival benefit with secondary cytoreductive surgery in
recurrent EOC was reported in the DESKTOP III trial in patients who underwent complete debulking
surgery [80] (and presented at ASCO2020). Studies have shown that fluorescence-guided surgical
procedures can lead to changes in the postsurgical treatment plan, mainly because of the identification
of additionally identified peritoneal and unresectable metastases [81].
CD24-targeted FIGS can improve the identification of disseminated metastases based on the
association of CD24 expression with an advanced stage and the metastatic activity of CD24+ tumor cells,
which exhibit fast tumor growth [17,82]. The increased expression of CD24 in metastatic tumors was
identified in 60 paired primary and metastatic lesions of bladder cancer [62]. We have demonstrated
that CD24-Alexa Fluor 680 can positively identify tumor lesions through non-invasive imaging at an
early stage of the disease, detect early metastatic dissemination, and allow the longitudinal evaluation
of tumor progression and treatment efficacy [19]. For real-time intraoperative fluorescence imaging,
conjugation to the NIR dye Alexa Fluor 750 improved its optical properties by allowing deeper tissue
penetration along with low tissue autofluorescence. FIGS enabled the intraoperative identification of
the primary tumor and miniscule metastases in seven heterogeneous CD24-expressing PDX models,
and ultimately improved tumor resection in preclinical orthotopic PDX [14]. CD24’s monoclonal
antibody-based fluorescence intensity peaked 48 h after injection. However, a tumor-specific
fluorescence signal was obtained for up to 120 h, demonstrating the long retention time of the
contrast agent [14]. CD24-targeting contrast agents can be further developed into smaller antibody
fragments, such as nanobodies and minibodies, which have favorable pharmacokinetic characteristics,
while maintaining their superior binding affinity [13,83]. Of note, in addition to the HGSOC subtype,
we extended their use to clear cell carcinoma and anaplastic carcinoma models, demonstrating the
versatility of CD24-targeted fluorescence imaging [14,19]. Our results suggest that CD24 is a promising
tumor target for FIGS in ovarian cancer patients, as it fulfils the requirements of a good biomarker for
the development of FIGS contrast agents (Figure 1). However, the increased expression of CD24 in
metastases compared to that in its matched primary lesion has not been confirmed for EOC.
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Figure 1. Requirements of a go d biomarker r fluorescenc image- uided surgery in the context
of CD24. It should have (1) high tumor specificity with high abundance on tumor cells, and (2)
the target should be absent in healthy tissue (3), while spatial and temporal intratumor heterogeneity
should be low [13]. (4) It should have broad applicability to a wide variety of malignancies and
(5) preferably extracellular target expression for better accessibility to widen its clinical applicability.
EMT: epithelial–mesenchymal transition; CSCs: cancer stem cells
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Aside from the overexpression of the target on various different malignancies, homogenous
biomarker expression is needed for broad clinical applicability. Notably, most tumor biomarkers,
including CD24, are heterogeneously expressed (Table 2). The heterogenous spatial and temporal inter-
and intratumoral expression can pose challenges for patient selection and fluorescent signal intensities
in FIGS. However, to overcome intratumoral heterogeneity, multiplexing strategies involving the use
of a cocktail of different contrast agents with different antigen specificities for FIGS might avoid patient
preselection and increase the contrast between healthy and tumor tissues [84,85].
CD24 has not only been correlated with clinicopathological parameters in EOC, but also
associated with tumor grade and overall survival in several other cancers [17,66,69,77,86] (Table 2).
To understand the relationship between CD24 and poor prognosis, CD24 expression has been linked
to biological characteristics. Four CD24-driven mechanisms have been described that indicate its
role in carcinogenesis, and therefore might explain its tumor-specific expression. First, CD24 is an
alternative ligand of P-selectin, an adhesion receptor expressed on activated endothelial cells and
platelets, promoting metastatic potential through binding CD24+ tumor cells [87]. A direct role in
metastatic progression has been described by Overdevest et al., who identified the correlation of CD24+
tumor cells with metastatic spread to the lungs in bladder carcinoma [62]. Second, CD24 has been
associated with epithelial–mesenchymal transition (EMT), a multistep process enabling the tumor cells
to invade and disseminate [66]. It has been suggested that CD24 affects the EMT signal cascade via the
PI3K/Akt/mTOR pathway and MAP kinase pathways, which imparts a high invasive capacity [66].
Third, cancer stem cells (CSCs), a continuously proliferating subset of cancer cells with stem-like
and tumor cell characteristics, express, among other markers, CD24, CD44, and CD133, and they
increase tumorigenic potential and drive growth and metastasis. CSCs are capable of generating the
full tumor heterogeneity that resembles the parental tumors, and are the main driver of an aggressive
disease course; thus, they are the target of many therapeutic approaches. CD24 is a CSC marker of
colorectal, pancreatic, hepatic, and nasopharyngeal cancers, as well as EOC. All tumors are amenable to
debulking surgery or wide local excision, and therefore, CD24-FIGS could aid in the complete resection
of peritoneal disseminated and metastatic disease [21]. Phosphorylated signal transducer and activator
of transcription 3 (STAT3), which is found primarily in CD24+ tumor cells, promotes the self-renewal
capacity of ovarian cancer CSCs, which also express higher mRNA levels of stemness genes [82,88,89].
Consequently, targeting CD24 with a monoclonal antibody in preclinical ovarian cancer cell line
models has been shown to decrease cell proliferation and tumor growth [90]. Growth inhibition
by inducting apoptosis following CD24-blockade has also been demonstrated in CD24-expressing
colorectal tumors in vivo [91]. Lastly, cytoplasmatic CD24 competitively inhibits the binding of the
tumor suppressor ARF to the nucleolar protein NPM, resulting in the inactivation and degradation of
ARF, increased MDM2 levels, and decreased p53 levels. This suggests that CD24 overexpression results
in the pro-tumorigenic inactivation of the tumor suppressor gene TP53 [92]. Another study reported
a high correlation between CD24 mRNA expression levels and p53 gene mutation in hepatocellular
carcinoma [71]. Interestingly, the cytoplasmatic expression of CD24 is associated with poor overall
survival in ovarian cancer, whereas CD24−CD44+ cells are an indicator of drug resistance [93]. It is,
however, important to note that membranous and cytoplasmatic CD24 have different biological
activities, and therefore comprise two independent prognostic markers. However, even though many
studies suggest a direct role of CD24 in tumor growth, invasiveness and migration, and the formation
of metastases, its potential molecular mechanisms are not fully understood [94].
In summary, CD24 demonstrates favorable biomarker characteristics, and when coupled with
advanced fluorescent dyes and antibody technologies that offer superior resolution and contrast,
CD24-targeted FIGS has the potential to improve the surgical resection of many types of tumors.
5. CD24 as a Bimodal Imaging Biomarker and Beyond
The association of CD24 expression with poor clinicopathological parameters suggests a direct
role of CD24 in tumorgenicity. Furthermore, the specific binding of CD24-targeting fluorescence
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contrast agents to CD24+ tumor cells has been reported in preclinical metastatic cell lines and PDX
models, which support its use as a theranostic biomarker [14,19]. CD24 has been investigated for use
in molecular targeted therapy, highlighting the potent anti-tumor effect of CD24 blockade and the
potential to unravel the blockade of the immune system, suggesting the potential of its use beyond
FIGS [16,90]. However, to date, bimodal CD24-targeting approaches have not been investigated.
Therefore, we propose the extension of CD24-targeted probes to (1) bimodal imaging contrast agents
and (2) dual-theranostic agents that incorporate its preoperative and/or intraoperative imaging and
targeted treatment characteristics.
The combination of radioactive tracers and NIR fluorescence molecules has been suggested
as an approach to overcome the limited tissue penetration depth of optical fluorescence imaging
while maintaining its superior spatial resolution. Even though NIR fluorophores exhibit a favorable
penetration depth of 5–7 mm in the NIR spectrum (700–900 nm) compared to 1–2 mm in the
visible spectrum (400–700), the detection of deeper localized metastases and preoperative staging are
hampered [95]. Nuclear gamma probes can be used for deep tissue detection below 1 cm, and the surgeon
can be guided via acoustic signals generated by a gamma probe counter in close proximity to the gamma
radiation-emitting targeted lesions, which can then be localized and delineated by their fluorescent
characteristics [96] (Figure 2A). Farletuzumab was introduced as a hybrid nuclear-fluorescent probe
for FIGS in preclinical metastatic ovarian cancer xenograft models. 111In-farletuzumab–IRDye800CW
allows the detection of deeply located tumors by radiation, while the accurate real-time delineation
of tumor metastases can be achieved by FIGS [47]. In addition, bimodal probes offer preoperative
tumor localization by positron emission tomography (PET) or single-photon emission computed
tomography (SPECT) for surgical planning, intraoperative guidance, and postoperative treatment.
The advantage of using both modalities was also demonstrated for 89Zr- and IRDye800CW-conjugated
pertuzumab in orthotopic Skov-3 xenograft models [41]. An optimal tumor-to-background ratio was
achieved for both PET and NIR fluorescence imaging after 24–72 h [41]. The circulation time of peptides
and antibodies corresponds well to the half-life of the commonly used radiotracers of several hours
(64Cu t1/2 12.7 h, PET) to a few days (111I t1/2 2.8 d, SPECT; 89Zr t1/2 3.3d PET). The complementary use
of both radioactivity and fluorescence in one injected dual-labeled tracer overcomes their individual
limitations [47,96]. Moreover, photo- (immuno or thermal) therapy involves the use of a photosensitizer
(e.g., Her2-affibody-NIR830, IR780-loaded folate-targeted nanoparticles), which exerts its cytotoxic
effect after NIR light exposure, helping to specifically ablate unresectable or missed tumor deposits
without destroying the surrounding tissue [49,97]. The CD24-NIR probe can be further developed into
a bimodal probe, expanding its use beyond intraoperative fluorescence guidance (Figure 2A).
Attempts have been made to therapeutically target CD24 using antibody–drug conjugates
(ADCs; mAb CD24-nitric oxide conjugate [15]), antibody-mediated cytotoxicity [90], immunotherapy
(anti-CD24-CAR-NK [98]), innate immune checkpoint inhibition [16], and bispecific antibodies [99]
(Figure 2B–D). The bimodal approach of fluorescence imaging and ADCs extends FIGS to include
highly selective drug delivery. The CD24-linked nitric oxide (HN-01)-targeted delivery system was
shown to induce apoptosis in CD24+ tumor cells after receptor-mediated internalization (Figure 2B).
Increased levels of nitric oxide were detected in the cytoplasm of CD24-overexpressing tumor cells,
resulting in tumor growth suppression in preclinical hepatic carcinoma xenograft models [15]. The use
of ADCs has been found to be successful in clinical trials. Mirvetuximab soravtansine is a monoclonal
antibody targeting FRα that is conjugated to the cytotoxic drug maytansinoid DM4, which directly
induces mitotic arrest in FRα+ tumors. The antitumor activity observed in preclinical studies of
EOC PDX models, together with favorable tolerability profiles in patients, led to a Phase Ib trial in
relapsed EOC patients (FORWARD II) [100,101]. The site-directed delivery of the cytotoxic drug in
combination with bevacizumab exhibited a similar efficacy to the standard treatment of paclitaxel
combined with bevacizumab in recurrent EOC, with favorable toxicity profiles [102]. Approaches to
site-specific transfer drugs to tumors have also been investigated by targeting the membrane-bound
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GPI-linked glycoprotein mesothelin (anetumab ravtansine) and the transmembrane mucin MUC16
(CA125; sofituzumab vedotin) in EOC [103].
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In addition, CD24 plays a role in immune inhibition. Aside from its interaction with
P-selectin, CD24 inte acts with sialic-acid-bindi g Ig-like lectin 10 (Siglec-10), a recept r expr ssed on
tumor-associated macrophages (TAMs) [16,104]. Cancer cells evade phagocytosis by TAMs through
the expression of the “don’t eat me”-receptors CD47, PD-L1, MHC-I β2 microglobulin subunit (b2m),
and CD24. As a result, inhibiting the interaction of CD24-Siglec-10 promotes the phagocytosis of
CD24+ tumor cells by TAMs, and has been shown to increase survival in preclinical mouse models [16]
(Figure 2D). Another approach to stimu ate the immune syst m nd targ t cancer stem cells is the
exploitation of engineered third-gen ration CD24-chimeri antigen receptor (CAR)-expressing natural
killer cells (CD24-CAR-NK cells) [98]. CD24-CAR-NK cells are activated following specific binding
to the SWA11-antigenic recognition site, and elicit cytotoxic activity against CD24+ tumor cell lines
(Skov-3, OVCAR3) and patient-derived primary ovarian cancer cells [98]. These studies demonstrate
that CD24 is a promising target for molecular targeted therapy, including inducing immune-mediated
and antibody-depe dent cell cytotoxicity (Figure 2). Consequently, CD24’s tumor specificity should be
exploited beyond fluorescent contrast agents.
6. Conclusions
Targeted fluorescence image-guided surgery provides additional crucial information about tumor
localization, tumor margins, and lymph node infiltration. To improve target specificity and decrease
unspecific signals, sever l biomarkers, such as CA125, EpCAM, VEGF, Her2, integrins, and GnRH
receptors, have been tested in preclinical and clinical trial of FIGS, as well as for other diagnostic
and therapeutic purposes in EOC. Based on this review, we propose that the small cell surface
protein CD24 is an ideal biomarker for FIGS. CD24 meets the criteria of a good imaging biomarker,
as it is almost uniquely expressed on tumor cells and predominantly physiologically expressed on
developing hematological cells, with low expression in healthy tissues. Its moderate spatial and
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temporal intratumor heterogenous expression in EOC enables its broad applicability among different
stages, in cases of recurrence, and in metastases. Finally, CD24 is expressed on almost 70% of solid
tumors, which makes CD24-FIGS suitable for a wide variety of malignancies. In a preclinical study of
EOC, CD24-NIR contrast agents were demonstrated to enable the enhanced detection of metastases
and an increased resection in heterogeneous CD24-expressing metastatic PDX models. As technology
improves, making it possible to produce dyes with favorable optical and physical properties and
spurring the development from mAb to antibody fragments and nanobodies, CD24-FIGS has the
potential to move to clinical use in EOC and various different cancer debulking and whole organ
excision surgeries. We anticipate that a bimodal approach using a CD24-targeted FIGS contrast agent
with antibody–drug conjugates, immune blockade, or immunostimulatory CARs may link precision
surgical therapy with the postsurgical irradiation of unresected tumor deposits, ultimately benefiting
cancer patients.
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